Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8d/b8/0f/8db80f81-2247-4672-914d-289f9cb6f61b/mza_3544939216694081436.jpg/600x600bb.jpg
The Long Run with Luke Timmerman
Timmerman Report
186 episodes
1 week ago
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
RSS
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
https://i1.sndcdn.com/avatars-000334687557-gwdmq9-original.jpg
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
The Long Run with Luke Timmerman
1 hour 2 minutes 28 seconds
11 months ago
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
The Long Run with Luke Timmerman
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.